Skip to main content
Top
Published in: Archives of Osteoporosis 1-2/2012

01-12-2012 | Original Article

Osteoporosis management and the utilization of FRAX®: a survey amongst health care professionals of the Asia-Pacific

Authors: Daniela Korthoewer, Manju Chandran, On behalf of the Endocrine and Metabolic Society of Singapore

Published in: Archives of Osteoporosis | Issue 1-2/2012

Login to get access

Abstract

Summary

This survey investigated osteoporosis management practices in the Asia-Pacific region. While access to anti-osteoporotic medication is reasonable, screening for secondary contributors is performed insufficiently. FRAX® is well-known, but not used by many physicians. High costs of medication and unawareness about the disease are the biggest barriers to osteoporosis care.

Purpose

Osteoporosis is an increasing burden amongst countries of the Asia-Pacific. The fracture risk assessment tool FRAX® has recently been introduced in some Asian countries. This study aimed to identify attitudes about osteoporosis management in general and the utilization of FRAX® in particular amongst physicians in the Asia-Pacific region.

Methods

A 26-item questionnaire was distributed to the participants of the first Asian regional osteoporosis meeting of the IOF in 2010. In total, 247 valid questionnaires representing 17 countries from the Asia-Pacific region were analyzed.

Results

Most physicians make use of bone densitometry devices (94 %) and have access to at least one type of anti-osteoporotic medication (100 %). Central dual-energy X-ray absorptiometry was the most accessible device (87 %). Oral bisphosphonates were the only medication that was available to health care professionals in all surveyed Asia-Pacific countries. Seventy-six percent were aware of FRAX®; however, among these only 62 % used it. The main reason for not using FRAX® was the lack of country-specific models (46 %). Screening for secondary osteoporosis was performed by 36 % of the respondents. The high costs of medication and lack of awareness amongst physicians and patients about the disease were perceived as the most important barriers to osteoporosis care.

Conclusion

More FRAX® models should be established and implemented into the local guidelines. The necessity of screening for secondary contributors to osteoporosis should be emphasized, as easily treatable causes might be identified. To further improve osteoporosis diagnosis and treatment, the awareness of osteoporosis among doctors as well as patients needs to be raised.
Literature
2.
go back to reference Cummings SR, Kelsey JL, Nevitt MC et al (1985) Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 7:178–208PubMed Cummings SR, Kelsey JL, Nevitt MC et al (1985) Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 7:178–208PubMed
3.
go back to reference Sanders KM, Nicholson GC, Ugoni AM et al (1999) Health burden of hip and other fractures in Australia beyond 2000. Projections based on the Geelong Osteoporosis Study. Med J Aust 170(10):467–470PubMed Sanders KM, Nicholson GC, Ugoni AM et al (1999) Health burden of hip and other fractures in Australia beyond 2000. Projections based on the Geelong Osteoporosis Study. Med J Aust 170(10):467–470PubMed
4.
go back to reference Riggs BL, Melton L (1995) The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17(5 Suppl):505S–511SPubMedCrossRef Riggs BL, Melton L (1995) The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17(5 Suppl):505S–511SPubMedCrossRef
9.
go back to reference Tamaki J, Iki M, Kadowaki E et al (2011) Fracture risk prediction using FRAX(R): a 10-year follow-up survey of the Japanese Population-Based Osteoporosis (JPOS) Cohort Study. Osteoporos Int 22(12):3037–3045. doi:10.1007/s00198-011-1537-x PubMedCrossRef Tamaki J, Iki M, Kadowaki E et al (2011) Fracture risk prediction using FRAX(R): a 10-year follow-up survey of the Japanese Population-Based Osteoporosis (JPOS) Cohort Study. Osteoporos Int 22(12):3037–3045. doi:10.​1007/​s00198-011-1537-x PubMedCrossRef
10.
go back to reference World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO technical report series World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO technical report series
11.
15.
go back to reference Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporosis Int 4(6):368–381. doi:10.1007/BF01622200 CrossRef Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporosis Int 4(6):368–381. doi:10.​1007/​BF01622200 CrossRef
16.
go back to reference Hans D, Kanis J, Baim S et al (2011) Joint official positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX((R)). Executive summary of the 2010 Position Development Conference on Interpretation and use of FRAX(R) in clinical practice. J Clin Densitom 14(3):171–180. doi:10.1016/j.jocd.2011.05.007 PubMedCrossRef Hans D, Kanis J, Baim S et al (2011) Joint official positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX((R)). Executive summary of the 2010 Position Development Conference on Interpretation and use of FRAX(R) in clinical practice. J Clin Densitom 14(3):171–180. doi:10.​1016/​j.​jocd.​2011.​05.​007 PubMedCrossRef
17.
go back to reference Lau EM, Lee JK, Suriwongpaisal P et al (2001) The incidence of hip fracture in four Asian countries: the Asian Osteoporosis Study (AOS). Osteoporos Int 12(3):239–243PubMedCrossRef Lau EM, Lee JK, Suriwongpaisal P et al (2001) The incidence of hip fracture in four Asian countries: the Asian Osteoporosis Study (AOS). Osteoporos Int 12(3):239–243PubMedCrossRef
18.
go back to reference Chandran M, Hoeck HC, Wong HC et al (2011) Vitamin D status and its relationship with bone mineral density and parathyroid hormone in Southeast Asian adults with low bone density. Endocr Pract 17(2):226–234. doi:10.4158/EP10202.OR PubMedCrossRef Chandran M, Hoeck HC, Wong HC et al (2011) Vitamin D status and its relationship with bone mineral density and parathyroid hormone in Southeast Asian adults with low bone density. Endocr Pract 17(2):226–234. doi:10.​4158/​EP10202.​OR PubMedCrossRef
21.
go back to reference National Osteoporosis Foundation (2010) Clinician's guide to prevention and treatment of osteoporosis. www.nof.org. Accessed 26 Mar 2012 National Osteoporosis Foundation (2010) Clinician's guide to prevention and treatment of osteoporosis. www.​nof.​org. Accessed 26 Mar 2012
22.
go back to reference Yung CK, Fook-Chong S, Chandran M (2012) The prevalence of recognized contributors to secondary osteoporosis in South East Asian men and post-menopausal women. Are Z score diagnostic thresholds useful predictors of their presence? Arch Osteoporos. doi:10.1007/s11657-012-0078-z Yung CK, Fook-Chong S, Chandran M (2012) The prevalence of recognized contributors to secondary osteoporosis in South East Asian men and post-menopausal women. Are Z score diagnostic thresholds useful predictors of their presence? Arch Osteoporos. doi:10.​1007/​s11657-012-0078-z
27.
go back to reference National Institutes for Health and Clinical Excellence (2011) Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures inpostmenopausal women (amended) (NICE technology appraisal guidance 160). Accessed 28 May 2012 National Institutes for Health and Clinical Excellence (2011) Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures inpostmenopausal women (amended) (NICE technology appraisal guidance 160). Accessed 28 May 2012
28.
go back to reference Salari P, Abdollahi M (2012) Long term bisphosphonate use in osteoporotic patients; a step forward, two steps back. J Pharm Pharm Sci 15(2):305–317PubMed Salari P, Abdollahi M (2012) Long term bisphosphonate use in osteoporotic patients; a step forward, two steps back. J Pharm Pharm Sci 15(2):305–317PubMed
30.
go back to reference Chan SP, Scott BB, Sen SS (2010) An Asian viewpoint on the use of vitamin D and calcium in osteoporosis treatment: physician and patient attitudes and beliefs. BMC Musculoskelet Disord 11:248. doi:10.1186/1471-2474-11-248 PubMed Chan SP, Scott BB, Sen SS (2010) An Asian viewpoint on the use of vitamin D and calcium in osteoporosis treatment: physician and patient attitudes and beliefs. BMC Musculoskelet Disord 11:248. doi:10.​1186/​1471-2474-11-248 PubMed
Metadata
Title
Osteoporosis management and the utilization of FRAX®: a survey amongst health care professionals of the Asia-Pacific
Authors
Daniela Korthoewer
Manju Chandran
On behalf of the Endocrine and Metabolic Society of Singapore
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
Archives of Osteoporosis / Issue 1-2/2012
Print ISSN: 1862-3522
Electronic ISSN: 1862-3514
DOI
https://doi.org/10.1007/s11657-012-0097-9

Other articles of this Issue 1-2/2012

Archives of Osteoporosis 1-2/2012 Go to the issue